Phenylbutyrate Counteracts Shigella Mediated Downregulation of Cathelicidin in Rabbit Lung and Intestinal Epithelia: A Potential Therapeutic Strategy
Open Access
- 3 June 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6), e20637
- https://doi.org/10.1371/journal.pone.0020637
Abstract
Cathelicidins and defensins are endogenous antimicrobial peptides (AMPs) that are downregulated in the mucosal epithelia of the large intestine in shigellosis. Oral treatment of Shigella infected rabbits with sodium butyrate (NaB) reduces clinical severity and counteracts the downregulation of cathelicidin (CAP-18) in the large intestinal epithelia. To develop novel regimen for treating infectious diseases by inducing innate immunity, we selected sodium 4-phenylbutyrate (PB), a registered drug for a metabolic disorder as a potential therapeutic candidate in a rabbit model of shigellosis. Since acute respiratory infections often cause secondary complications during shigellosis, the systemic effect of PB and NaB on CAP-18 expression in respiratory epithelia was also evaluated. The readouts were clinical outcomes, CAP-18 expression in mucosa of colon, rectum, lung and trachea (immunohistochemistry and real-time PCR) and release of the CAP-18 peptide/protein in stool (Western blot). Significant downregulation of CAP-18 expression in the epithelia of rectum and colon, the site of Shigella infection was confirmed. Interestingly, reduced expression of CAP-18 was also noticed in the epithelia of lung and trachea, indicating a systemic effect of the infection. This suggests a causative link to acute respiratory infections during shigellosis. Oral treatment with PB resulted in reduced clinical illness and upregulation of CAP-18 in the epithelium of rectum. Both PB and NaB counteracted the downregulation of CAP-18 in lung epithelium. The drug effect is suggested to be systemic as intravenous administration of NaB could also upregulate CAP-18 in the epithelia of lung, rectum and colon. Our results suggest that PB has treatment potential in human shigellosis. Enhancement of CAP-18 in the mucosal epithelia of the respiratory tract by PB or NaB is a novel discovery. This could mediate protection from secondary respiratory infections that frequently are the lethal causes in dysentery.Keywords
This publication has 36 references indexed in Scilit:
- Phenylbutyrate Induces Antimicrobial Peptide ExpressionAntimicrobial Agents and Chemotherapy, 2009
- Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43Nature, 2009
- Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expressionThe Journal of Experimental Medicine, 2008
- Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibioticProceedings of the National Academy of Sciences of the United States of America, 2006
- Determination of tributyrin and its metabolite butyrate in Wistar rat plasma samples by gas chromatography/mass spectrometryRapid Communications in Mass Spectrometry, 2004
- Antimicrobial peptides of multicellular organismsNature, 2002
- Spontaneous secretion of interferon γ and interleukin 4 by human intraepithelial and lamina propria gut lymphocytesGut, 1998
- Diarrheal Epidemics Among Rwandan Refugees in 1994Journal of Clinical Gastroenterology, 1997
- Causes of death and the histopathologic findings in fatal shigellosisThe Pediatric Infectious Disease Journal, 1989
- The Biology of Cachectin/TNF -- A Primary Mediator of the Host ResponseAnnual Review of Immunology, 1989